Literature DB >> 22441439

Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.

L Stingl1, N Niewidok, N Müller, M Selle, C S Djuzenova, M Flentje.   

Abstract

BACKGROUND: Hsp90 inhibitors can enhance the tumour sensitivity to ionising radiation (IR). However, Hsp90 inhibition leads to the up-regulation of anti-apoptotic Hsp90 and Hsp70, which might diminish the radiosensitizing effects of the inhibitors. Therefore, inhibition of the up-regulation of Hsp90 by siRNA might be a promising strategy to enhance drug-mediated radiosensitization.
MATERIALS AND METHODS: The expression of Hsp90α was silenced in A549 and GaMG tumour cell lines by siRNA treatment. Pre-silenced for Hsp90α cells were treated with NVP-AUY922, a novel Hsp90 inhibitor, for 24 h and then irradiated. Radiation response was determined by colony-forming ability. The expression of several marker proteins was analysed by Western blot. DNA damage and repair were assessed by histone γH2AX measurements.
RESULTS: We found that transfection with siRNA against Hsp90α reduced Hsp90α at mRNA and protein levels. Pre-silencing of Hsp90α reduced NVP-AUY922-mediated up-regulation of Hsp90α but it did not increase drug-mediated radiosensitization in both tumour cell lines. As revealed by Western blot, pre-silencing of Hsp90α followed by NVP-AUY922 did not change the expression of Hsp90 client proteins (Akt, Raf-1, Cdk1 and Cdk4) compared with drug treatment alone, suggesting unchanged chaperone function in transfected cells.
CONCLUSION: Pre-silencing of Hsp90α followed by Hsp90 inhibition did not enhance the radiosensitizing effect of NVP-AUY922 in both tested tumour cell lines. Future work will be done on stable transfection with shRNA against Hsp90α or simultaneous silencing of both Hsp90 isoforms, Hsp90α and Hsp90β, in order to optimize tumour cell killing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441439     DOI: 10.1007/s00066-012-0080-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Hsp90 isoforms: functions, expression and clinical importance.

Authors:  Amere Subbarao Sreedhar; Eva Kalmár; Péter Csermely; Yu-Fei Shen
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

3.  Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling.

Authors:  Marek Los; Malgorzata Mozoluk; Davide Ferrari; Anna Stepczynska; Christopher Stroh; Andrea Renz; Zdenko Herceg; Zhao-Qi Wang; Klaus Schulze-Osthoff
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

4.  DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.

Authors:  E P Rogakou; D R Pilch; A H Orr; V S Ivanova; W M Bonner
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

5.  Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?

Authors:  Nichola Cruickshanks; Leroy Shervington; Rahima Patel; Chinmay Munje; Dipti Thakkar; Amal Shervington
Journal:  Cancer Invest       Date:  2010-07       Impact factor: 2.176

6.  Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells.

Authors:  Frederick Mantel; Benjamin Frey; Stefan Haslinger; Petra Schildkopf; Renate Sieber; Oliver J Ott; Barbara Lödermann; Franz Rödel; Rolf Sauer; Rainer Fietkau; Udo S Gaipl
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

7.  Gene expression signatures in the peripheral blood after radiosurgery of human cerebral arteriovenous malformations.

Authors:  Angelika Zabel-du Bois; Mechthild Wagner-Ecker; Stefanie Milker-Zabel; Christian Schwager; Ute Wirkner; Jürgen Debus; Amir Abdollahi; Peter E Huber
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

8.  Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

Authors:  Mahmoud Toulany; Rainer Kehlbach; Urszula Florczak; Ali Sak; Shaomeng Wang; Jianyong Chen; Markus Lobrich; H Peter Rodemann
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

Review 9.  RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets.

Authors:  Marco Folini; Marzia Pennati; Nadia Zaffaroni
Journal:  Methods Mol Biol       Date:  2009

10.  Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients.

Authors:  C Djuzenova; B Mühl; R Schakowski; U Oppitz; M Flentje
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  4 in total

1.  The effect of resveratrol in combination with irradiation and chemotherapy: study using Merkel cell carcinoma cell lines.

Authors:  G Heiduschka; C Lill; R Seemann; M Brunner; R Schmid; R Houben; J Bigenzahn; D Thurnher
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

2.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Authors:  Nishant Gandhi; Aaron T Wild; Sivarajan T Chettiar; Khaled Aziz; Yoshinori Kato; Rajendra P Gajula; Russell D Williams; Jessica A Cades; Anvesh Annadanam; Danny Song; Yonggang Zhang; Russell K Hales; Joseph M Herman; Elwood Armour; Theodore L DeWeese; Edward M Schaeffer; Phuoc T Tran
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 3.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

4.  Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.

Authors:  Cholpon S Djuzenova; Vanessa Fiedler; Astrid Katzer; Konstanze Michel; Stefanie Deckert; Heiko Zimmermann; Vladimir L Sukhorukov; Michael Flentje
Journal:  Oncotarget       Date:  2016-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.